BMY

Business profile & competitive position

Bristol-Myers Squibb Company is a single-segment biopharmaceutical company engaged in the full lifecycle of innovative medicines—discovery, development, licensing, manufacturing, marketing, distribution, and sale—targeting serious diseases. Its therapeutic focus areas are oncology, hematology, immunology, cardiovascular, and neuroscience, and its products reach patients worldwide. The company principally sells to wholesalers, distributors, and specialty pharmacies, with smaller channels including retailers, hospitals, clinics, government agencies, and direct-to-patient routes.

The financial profile implies a business built on protected specialty franchises and scale. Total revenues were $48.194 billion in 2025, nearly flat with $48.300 billion in 2024 and up from $45.006 billion in 2023. Geographic concentration is meaningful: 69% of 2025 revenues came from the United States, 29% from International markets, and 2% from Other. A net margin of 18.9% and an ROE of 46.8% together point to genuine pricing power and capital efficiency—both classic hallmarks of an established pharmaceutical moat built on patented therapies, entrenched payer relationships, and multi-year development cycles that are difficult to replicate.

Financial posture

Bristol-Myers Squibb currently carries a market capitalization of $130.0 billion and trades at a P/E ratio of 14.0. A net margin of 18.9% and ROE of 46.8% are strong in absolute terms, while a beta of just 0.23 indicates the stock has historically moved much less than the broader market, consistent with the defensive profile often associated with large-cap healthcare.

The P/E of 14.0 sits below the multiples typically awarded to faster-growing biotech or tech-heavy healthcare names, which can reflect either a value-leaning rerating or investor caution around pipeline transition risk. The combination of high ROE and a moderate P/E multiple suggests the market is not fully pricing the company for aggressive growth, even though profitability remains substantial. The low beta reinforces that the stock is viewed as a relative safe-haven equity, but it does not eliminate company-specific risks such as patent expirations or clinical trial setbacks.

Strategic priorities & outlook

In its most recent 10-K filing, Bristol-Myers outlines four operational priorities: focusing on transformational medicines where it holds a competitive advantage, driving operational excellence across the organization, strategically allocating capital for long-term growth and shareholder returns, and executing commercially on key first-in-class and/or best-in-class marketed products.

R&D spending underscores the pipeline bet: $10.0 billion in 2025, down from $11.2 billion in 2024 and up from $9.3 billion in 2023, with more than 45 unique assets currently in development. The 2025 business-development agenda was active, including the acquisition of Orbital Therapeutics, a global strategic collaboration with BioNTech, and a global exclusive licensing agreement with Philochem. These moves align with the stated goal of refilling the pipeline through a mix of internal research and external partnerships, a pattern typical of large pharma seeking to offset revenue pressure from maturing blockbusters.

Macro & geopolitical exposure

As a Healthcare / Drug Manufacturers - General company, Bristol-Myers is exposed to the sector's defining macro forces: drug-pricing regulation, FDA and ex-U.S. regulatory approvals, government reimbursement policies, and international trade and currency dynamics. With 29% of 2025 revenue derived from International markets, foreign-exchange fluctuations and country-specific pricing negotiations can move reported results even when underlying demand is stable.

Broader policy risks include Medicare/Medicaid pricing reform, importation debates, and trade tariffs that can affect both finished-product flows and active pharmaceutical ingredient supply chains. Patent cliffs remain a persistent industry-wide factor for drug manufacturers, making the timing of new product launches and label extensions critical to revenue trajectories. None of these forces are unique to Bristol-Myers, but they are material context for any large-cap pharma equity.

Recent developments

The most recent news flow around Bristol-Myers has centered on investment strategy and income characteristics rather than clinical trial updates. On September 13, 2026, fool.com published "Should You Buy Bristol Myers Squibb Stock Right Now for the Yield Alone?," while 247wallst.com asked on September 12, 2026, "How Much Do You Really Need Invested in Bristol Myers Squibb to Collect $10,000 a Year?" Both headlines reflect a market conversation that treats the stock partly as an income vehicle.

Zacks.com contributed two performance-oriented pieces on September 10, 2026: "Bristol Myers Squibb (BMY) Declines More Than Market: Some Information for Investors" and "BMY Gains 19.4% Year to Date: Should You Buy, Sell or Hold the Stock?" Taken together, the coverage highlights a near-term tension: Bristol-Myers has posted a solid year-to-date gain of 19.4%, yet it has recently underperformed on a daily or weekly basis. The current price of $63.64 sits almost exactly on the 50-day EMA of $63.70, with an RSI of 42.4 suggesting neither overbought nor deeply oversold conditions.

Earnings behavior & post-earnings drift

Bristol-Myers has an unusual recent earnings record. Over the last eight reported quarters, the company has beaten the market's real expectation every time, for a beat rate of 8/8 (100%), with an average earnings surprise of 17.2%. On the surface, that looks like a consistent pattern of outperformance.

The post-earnings price behavior, however, tells a different story. The average 5-day price move following the past eight earnings releases is -1.37%, classified as a "down" drift. In other words, even when Bristol-Myers beats estimates, the stock has not reliably continued higher after the report. This disconnect matters for traders who assume "beat equals pop and hold." The unofficial consensus may be pricing in more than the published estimate, or investors may be selling the news and redirecting attention to guidance, pipeline updates, or patent-cliff concerns.

The last four quarters illustrate the variability. On July 30, 2026, Bristol-Myers reported EPS of $2.04 versus an estimate of $1.60, a 27.5% surprise, yet the stock rose only 0.69% the next day and fell 1.09% over the following five sessions. On April 30, 2026, EPS of $1.58 beat the $1.42 estimate by 11.3%, but the stock dropped 3.91% the next day and 7.16% over five days. The February 5, 2026 report delivered a slimmer 2.4% beat ($1.26 vs. $1.23 estimate) but produced a 4.15% next-day gain and a 0.57% five-day gain. The October 30, 2025 quarter saw a 7.2% beat ($1.63 vs. $1.52), with the stock gaining 0.99% the next day and 2.21% over five days. Looking ahead, the next scheduled report is October 29, 2026, before the open, with a consensus EPS estimate of $1.68.

For readers weighing how to interpret an upcoming print, the lesson is that headline beats are only part of the picture. The magnitude of the surprise, the direction of management commentary, and the market's real expectation all combine to determine whether the post-earnings drift continues upward or reverses.

If you want a fuller picture of how institutional analysts are interpreting Bristol-Myers' pipeline, capital allocation, and earnings setup, it is worth reviewing the complete institutional verdict alongside your own due diligence.